Back to Results

Trevi Therapeutics Inc (TRVI)

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company listed on NASDAQ under the symbol TRVI. The company is focused on developing and commercializing therapies for chronic cough, including cough associated with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, as well as refractory chronic cough. Its lead product candidate, Haduvio, is an oral extended-release formulation of nalbuphine that is being studied in a phase 2b clinical trial for chronic cough in IPF and in a phase 2a study for refractory chronic cough. Trevi also has a license agreement with Keenova Therapeutics plc covering products based on nalbuphine hydrochloride in different formulations. Founded in 2011, the company is headquartered in New Haven, Connecticut.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Price-to-Book Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-TRVI
$9.18
-28.3% Downside
Overvalued
$28.18
120.0% Upside
Bargain
Good
0.0%
5.7x
1.825 B
1.507 B
0.0%
83.0%
120.5
103.4%
Valuation • Fair Value

Trevi Therapeutics Inc (NASDAQ-TRVI) Fair Value by Valuation Model

Review the available estimates for Trevi Therapeutics Inc (NASDAQ-TRVI), including Comps Fair Value.

Primary Valuation Read

Fair Value

$9.18

Estimated downside of 28.3% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$9.18

Comparable-company valuation reference.

Analyst Price Target

$28.18

Analysts imply upside of 120.0%.

How to read these valuation models

Use the 4 available valuation references for Trevi Therapeutics Inc (NASDAQ-TRVI) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Trevi Therapeutics Inc (NASDAQ-TRVI)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-59.42 M

Current operating profitability reference.

EBITDA Forecast

-80.421 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Trevi Therapeutics Inc (NASDAQ-TRVI) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Trevi Therapeutics Inc (NASDAQ-TRVI)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Good

Positive financial-health read.

Piotroski Score

3

Weak quality score that deserves closer review.

Altman Z-Score

120.5

Relatively strong balance-sheet zone.

FCF / Net Income

103.4%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Trevi Therapeutics Inc (NASDAQ-TRVI). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Dividend Profile for Trevi Therapeutics Inc (NASDAQ-TRVI)

Review the dividend metrics currently supported by the latest data.

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

The latest data indicates no current dividend yield for Trevi Therapeutics Inc (NASDAQ-TRVI). No upcoming dividend amount or event date is currently available.

Stock Forecast • Technical Outlook

Trevi Therapeutics Inc (NASDAQ-TRVI) Stock Forecast & Technical Outlook

Review Trevi Therapeutics Inc (NASDAQ-TRVI) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Trevi Therapeutics Inc (NASDAQ-TRVI) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Trevi Therapeutics Inc (NASDAQ-TRVI) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Trevi Therapeutics Inc (NASDAQ-TRVI) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Trevi Therapeutics Inc (NASDAQ-TRVI) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Neutral

The monthly technical read for Trevi Therapeutics Inc (NASDAQ-TRVI) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Trevi Therapeutics Inc (NASDAQ-TRVI)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Trevi Therapeutics Inc (NASDAQ-TRVI) has a Strong Buy consensus, with 9 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 9
Hold 0
Sell 0
FAQ • Fast Investor Answers

Trevi Therapeutics Inc (NASDAQ-TRVI) Stock FAQ

Data-supported answers about Trevi Therapeutics Inc (NASDAQ-TRVI), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$9.18
Estimated downside 28.3%
Valuation Rating
Overvalued
Estimated downside of 28.3%
Analyst Target
$28.18
Implied upside 120.0%
Financial Health
Good
Current financial-health read

The current fair value estimate for Trevi Therapeutics Inc (NASDAQ-TRVI) is $9.18. This implies an estimated downside of 28.3% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 28.3% versus the current market price.

The available analyst price target for Trevi Therapeutics Inc (NASDAQ-TRVI) is $28.18. The analyst target implies estimated upside of 120.0%.

The current financial health read for Trevi Therapeutics Inc (NASDAQ-TRVI) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The latest available data indicates no current dividend yield for Trevi Therapeutics Inc (NASDAQ-TRVI).

The current market capitalization listed for Trevi Therapeutics Inc is 1.825 B.

The current enterprise value listed for Trevi Therapeutics Inc is 1.507 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Trevi Therapeutics Inc is NASDAQ-TRVI, and the stock is listed on NASDAQ.

Trevi Therapeutics Inc (NASDAQ-TRVI) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Trevi Therapeutics Inc is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Trevi Therapeutics Inc is 83.0%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,215.6 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 655.6 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 362.2 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 310 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 179.5 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 170.3 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 129 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 113.6 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 101.9 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 69.723 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 48.75 B
HLN NYSE HALEON PLC ADR Fair Value Undervalued Market Cap 40.368 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 38.751 B
ZTS NYSE Zoetis Inc Fair Value Undervalued Market Cap 33.93 B
VTRS NASDAQ Viatris Inc Fair Value Fair Market Cap 21.789 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Undervalued Market Cap 14.59 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 11.996 B
ELAN NYSE Elanco Animal Health Fair Value Overvalued Market Cap 11.831 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Fair Market Cap 7.834 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Undervalued Market Cap 6.827 B